

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-8. (canceled)

9. (new) A regime for determining whether or not a sample of skin or of a skin equivalent contains an amount of a papillary fibroblast population so as to be considered a normal skin, comprising labeling the skin or skin equivalent with at least one antibody specific for papillary fibroblasts, and evaluating any labeling to determine whether the skin or skin equivalent is a normal skin, wherein the presence of labeling indicates that the skin or skin equivalent is a normal skin and wherein the at least one antibody comprises a PG4 monoclonal antibody.

10. (new) The regime of claim 9, wherein the labeling is present at the upper dermis at the level of the epidermis.

11. (new) A regime for determining the presence of papillary fibroblasts in a given sample, comprising: labeling said sample with at least one antibody specific for papillary fibroblasts, and

evaluating any labeling as a marker for the presence of said papillary fibroblasts, wherein the at least one antibody comprises a PG4 monoclonal antibody.

12. (new) The regime of Claim 11, wherein the sample is a skin or skin equivalent sample.

13. (new) The regime of Claim 12, wherein the labeling is present at the upper dermis at the level of the epidermis in the skin or skin equivalent sample.